Press Release

Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market to Grow at a CAGR of 8.3% During 2024-2032, Aided by Intensive Efforts Across Market and Academia to Develop Novel Treatment Options

Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market

According to a new report by EMR titled, ‘Global Focal Segmental Glomerulosclerosis (FSGS) Treatment Market Report and Forecast 2024-2032’, the market attained a value of nearly USD 23.60 billion in 2023. The market is estimated to grow at a CAGR of 8.3% between 2024 and 2032 to reach around USD 48.17 billion by 2032.

The clinical presentation of FSGS includes symptoms consistent with nephrotic syndrome such as peripheral oedema, significant proteinuria that may be at nephrotic levels, hypertension, hypoalbuminemia, hyperlipidemia, and deteriorating renal function over time. FSGS can occur primarily or develop secondarily due to other conditions.


The focal segmental glomerulosclerosis (FSGS) treatment market growth is being driven by the rising production of pharmaceutical products and increased research and development efforts focused on biopharmaceuticals to improve treatment efficacy. Growth in generic drug production is also anticipated to contribute to market expansion. Additionally, advancements in developing treatments for rare diseases represent important potential opportunities for the market growth during the forecast period.


The ageing population, rising incidence of risk factors like diabetes and hypertension, and availability of advanced diagnostic and treatment options are further contributing to the market expansion. In February 2023, Travere Therapeutics, Inc. (NASDAQ: TVTX) announced that the United States Food and Drug Administration (FDA) has granted accelerated approval to FILSPARITM (sparsentan) for reducing proteinuria in adults with primary IgA nephropathy at high risk of rapidly progressing disease, generally indicated by a urine protein-to-creatinine ratio (UPCR) greater than or equal to 1.5 grams per gram.


Read more about this report REQUEST FREE SAMPLE COPY IN PDF


Market Breakup by Disease Type, Diagnosis Method, Treatment Method, Treatment Channel, and Region:

  • On the basis of the disease type, the market is bifurcated into primary focal segmental glomerulosclerosis and secondary focal segmental glomerulosclerosis.
  • The market is segmented based on diagnosis methods into kidney function testing, kidney imaging, and kidney biopsy.
  • On the basis of the treatment method, the market is divided into medication, dialysis, and kidney transplant.
  • The market is segmented based on treatment channel into public and private.
  • By region, the market can be divided into North America, Europe, the Asia Pacific, Latin America, and the Middle East and Africa.


Key Findings of the Report:

  • The increasing prevalence of focal segmental glomerulosclerosis (FSGS) and a strong emphasis on discovering novel therapeutic options are anticipated to substantially contribute to the focal segmental glomerulosclerosis (FSGS) treatment market expansion over the coming years.
  • Several rising risk factors are driving the market. These include increasing rates of kidney infections, greater exposure to toxins, more genetic mutations, and a growing prevalence of underlying conditions such as HIV and sickle cell disease.
  • The widespread use of certain medications that damage renal podocytes, including bisphosphonates, anabolic steroids, anthracyclines, and calcineurin inhibitors, is also driving the market growth. Furthermore, the increasing utilisation of corticosteroids in the treatment of FSGS, which prevent the immune system from attacking the glomeruli and affecting renal function, represents another factor propelling the market.
  • In addition, the growing use of plasmapheresis to decrease proteinuria and enhance kidney function in patients is further generating a favourable outlook for the market.


Key Offerings of the Report:

  • The EMR report gives an overview of the global focal segmental glomerulosclerosis (FSGS) treatment market for the periods (2017-2023) and (2024-2032).
  • The report also offers historical (2017-2023) and forecast (2024-2032) market information for the disease types, diagnosis methods, treatment methods, treatment channels, and major regions of focal segmental glomerulosclerosis (FSGS) treatment.
  • The report analyses the market dynamics, covering the key demand and price indicators in the market, industry events, initiatives, and trends, value chain analysis, along with providing an assessment of the SWOT and Porter’s Five Forces models.


The major players in the global focal segmental glomerulosclerosis (FSGS) treatment market are Beckman Coulter Inc. (Danaher Corporation), Complexa Inc., Variant Pharmaceuticals, Inc., Travere Therapeutics, Inc., Sanofi S.A., Pfizer Inc., GlaxoSmithKline Plc., Aurinia Pharmaceuticals Inc., Medtronic Plc., B. Braun Melsungen AG, Bristol-Myers Squibb Co, Reata Pharmaceuticals Inc, Kyowa Hakko Kirin Co., Ltd., and Astellas Pharma Inc., among others. The comprehensive report by EMR looks into the market share, capacity, and latest developments like mergers and acquisitions, plant turnarounds, and capacity expansions of the major players.


Key Highlights of the Report

Base Year 2023
Historical Period 2017-2023
Forecast Period 2024-2032
Scope of the Report

Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:

  • Disease Type
  • Diagnosis Method
  • Treatment Method
  • Treatment Channel
  • Region
Breakup by Disease Type
  • Primary Focal Segmental Glomerulosclerosis
  • Secondary Focal Segmental Glomerulosclerosis
Breakup by Diagnosis Method
  • Kidney Function Testing
  • Kidney Imaging
  • Kidney Biopsy
Breakup by Treatment Method
  • Medication
  • Dialysis
  • Kidney Transplant
Breakup by Treatment Channel
  • Public
  • Private
Breakup by Region
  • North America
  • Europe
  • Asia Pacific
  • Latin America
  • Middle East and Africa
Market Dynamics
  • Market Drivers and Constraints
  • SWOT Analysis
  • Porter’s Five Forces Model
  • Key Demand Indicators 
  • Key Price Indicators
  • Industry Events, Initiatives, and Trends
  • Value Chain Analysis
Competitive Landscape
  • Market Structure
  • Company Profiles
    • Company Overview
    • Product Portfolio
    • Demographic Reach and Achievements
    • Mergers and Acquisitions
    • Certifications
Companies Covered
  • Beckman Coulter Inc. (Danaher Corporation)
  • Complexa Inc.
  • Variant Pharmaceuticals, Inc.
  • Travere Therapeutics, Inc.
  • Sanofi S.A.
  • Pfizer Inc.
  • GlaxoSmithKline Plc.
  • Aurinia Pharmaceuticals Inc.
  • Medtronic Plc.
  • B. Braun Melsungen AG
  • Bristol-Myers Squibb Co
  • Reata Pharmaceuticals Inc
  • Kyowa Hakko Kirin Co., Ltd.
  • Astellas Pharma Inc.


About Us:

Expert Market Research (EMR) is a leading market research and business intelligence company, ensuring its clients remain at the vanguard of their industries by providing them with exhaustive and actionable market data through its syndicated and custom market reports, covering over 15 major industry domains. The company's expansive and ever-growing database of reports, which are constantly updated, includes reports from industry verticals like chemicals and materials, food and beverages, energy and mining, technology and media, consumer goods, pharmaceuticals, agriculture, and packaging.


EMR leverages its state-of-the-art technological and analytical tools, along with the expertise of its highly skilled team of over a 100 analysts and more than 3000 consultants, to help its clients, ranging from Fortune 1000 companies to small and medium sized enterprises, easily grasp the expansive industry data and help them in formulating market and business strategies, which ensure that they remain ahead of the curve.


Contact Us:

Expert Market Research
US & Canada Phone no: +1-415-325-5166
UK Phone no: +44-702-402-5790


*At Expert Market Research, we strive to always give you current and accurate information. The numbers depicted in the description are indicative and may differ from the actual numbers in the final EMR report.

Why Expert Market Research?

Right People

We are technically excellent, strategic, practical, experienced and efficient; our analysts are hand-picked based on having the right attributes to work successfully and execute projects based on your expectations.

Right Methodology

We leverage our cutting-edge technology, our access to trusted databases, and our knowledge of the current models used in the market to deliver you research solutions that are tailored to your needs and put you ahead of the curve.

Right Price

We deliver in-depth and superior quality research in prices that are reasonable, unmatchable, and shows our understanding of your resource structure. We, additionally, offer attractive discounts on our upcoming reports.

Right Support

Our team of expert analysts are at your beck and call to deliver you optimum results that are customised to meet your precise needs within the specified timeframe and help you form a better understanding of the industry.